000101544 001__ 101544
000101544 005__ 20230519145357.0
000101544 0247_ $$2doi$$a10.3390/jcm10050945
000101544 0248_ $$2sideral$$a124016
000101544 037__ $$aART-2021-124016
000101544 041__ $$aeng
000101544 100__ $$0(orcid)0000-0001-7293-701X$$aAguilar-Palacio, Isabel$$uUniversidad de Zaragoza
000101544 245__ $$aPharmacological primary cardiovascular prevention and subclinical atherosclerosis in men: Evidence from the aragon workers'' health study
000101544 260__ $$c2021
000101544 5060_ $$aAccess copy available to the general public$$fUnrestricted
000101544 5203_ $$aThe objective of this study is to describe the profile of primary preventive treatment for cardiovascular disease in adult males and to analyze the association between treatment profile and subclinical atherosclerosis. We selected male workers who had undergone ultrasound imaging and had no previous history of cardiovascular disease (n = 2138). Data on the consumption of primary cardiovascular drugs from the previous year were obtained. We performed bivariate analyses to compare patient characteristics according to cardiovascular treatment and the presence of subclinical atherosclerosis, and logistic regression models to explore the association between these two variables. Among participants with no personal history of cardiovascular disease, subclinical atherosclerosis was present in 77.7% and 31.2% had received some form of preventive treatment. Of those who received no preventive treatment, 73.6% had subclinical atherosclerosis. Cardiovascular preventive treatment was associated only with CACS > 0 (odds ratio (OR), 1.37; 95% confidence interval (95% CI), 1.06-1.78). Statin treatment was associated with a greater risk of any type of subclinical atherosclerosis (OR, 1.73) and with CACS > 0 (OR, 1.72). Subclinical atherosclerosis existed in almost 75% of men who had no personal history of cardiovascular disease and had not received preventive treatment for cardiovascular disease.
000101544 536__ $$9info:eu-repo/grantAgreement/ES/MICINN-ISCIII-FEDER/PI17-011704
000101544 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000101544 590__ $$a4.964$$b2021
000101544 592__ $$a1.04$$b2021
000101544 594__ $$a4.4$$b2021
000101544 591__ $$aMEDICINE, GENERAL & INTERNAL$$b55 / 172 = 0.32$$c2021$$dQ2$$eT1
000101544 593__ $$aMedicine (miscellaneous)$$c2021$$dQ1
000101544 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000101544 700__ $$0(orcid)0000-0002-7194-8275$$aMalo, Sara$$uUniversidad de Zaragoza
000101544 700__ $$0(orcid)0000-0001-9142-0737$$aJarauta, Estibaliz$$uUniversidad de Zaragoza
000101544 700__ $$0(orcid)0000-0003-0604-5042$$aMoreno-Franco, Belén$$uUniversidad de Zaragoza
000101544 700__ $$0(orcid)0000-0003-1647-3462$$aMaldonado, Lina$$uUniversidad de Zaragoza
000101544 700__ $$aCompés, Luisa
000101544 700__ $$0(orcid)0000-0002-6671-5661$$aRabanaque, José$$uUniversidad de Zaragoza
000101544 700__ $$0(orcid)0000-0002-9887-2629$$aCasasnovas, José Antonio$$uUniversidad de Zaragoza
000101544 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000101544 7102_ $$14014$$2623$$aUniversidad de Zaragoza$$bDpto. Economía Aplicada$$cÁrea Métodos Cuant.Econ.Empres
000101544 7102_ $$11011$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Medic.Prevent.Salud Públ.
000101544 773__ $$g10, 5 (2021), [11 pp.]$$pJ. clin.med.$$tJournal of Clinical Medicine$$x2077-0383
000101544 8564_ $$s256994$$uhttps://zaguan.unizar.es/record/101544/files/texto_completo.pdf$$yVersión publicada
000101544 8564_ $$s2677446$$uhttps://zaguan.unizar.es/record/101544/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000101544 909CO $$ooai:zaguan.unizar.es:101544$$particulos$$pdriver
000101544 951__ $$a2023-05-18-13:34:41
000101544 980__ $$aARTICLE